Collaboration, License and Research Agreements - Additional Information (Details)		1 Months Ended		12 Months Ended
	Nov. 27, 2023 USD ($) shares	Nov. 30, 2023 USD ($) $ / shares shares	Apr. 30, 2019 USD ($) Product Obligation	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue				$ 9,560,000	$ 9,224,000	$ 9,326,000
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fees received		$ 100,000,000
Collaborative arrangement, nonrefundable cash payment received		60,000,000
Sale of stock, consideration received on transaction		40,000,000
Cumulative spending cap		40,000,000
Period for expected performance obligation				7 years
Collaboration revenue				$ 0
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS | First Unit Of Accounting
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue, remaining performance obligation, amount		68,700,000
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS | Second Unit Of Accounting
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue, remaining performance obligation, amount		$ 31,300,000
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS | Private Placement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sale of stock number of shares issued in transaction (in shares) | shares	5,075,304	5,075,304
Sale of stock, consideration received on transaction	$ 40,000,000	$ 40,000,000
Sale of stock, price per share (in dollars per share) | $ / shares		$ 7.8813
Premium In excess of fair value		$ 8,700,000
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payment eligible to receive		1,350,000,000
Commercialization milestone payment eligible to receive		$ 825,000,000
Research Collaboration and License Agreement with Eli Lilly
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fees received			$ 20,000,000
Period for expected performance obligation				5 years
Collaboration revenue				$ 9,500,000	9,000,000	$ 9,100,000
License agreement expiry period			10 years
Number of performance obligation | Obligation			1
Collaboration receivables				$ 800,000	$ 2,100,000
Research Collaboration and License Agreement with Eli Lilly | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payment eligible to receive			$ 60,000,000
Commercialization milestone payment eligible to receive			$ 205,000,000
Rights to antibody oligonucleotide conjugates for messengers RNA targets. | Product			6
Regulatory milestone payment eligible to receive			$ 140,000,000